Personalis Q2 revenue rises 30% to $22.4 million on surging clinical test volume

• Personalis posted Q2 revenue of $22.4 million, up 30% from $17.2 million.
• Clinical revenue rose 442% to $2.6 million from $0.5 million; clinical test volume jumped 199% to 10,384 tests.
• Pharma testing services and other customer revenue increased 51% to $16.8 million; VA MVP population sequencing revenue fell 9% to $3 million.
• Cash, cash equivalents, short-term investments totaled about $212.7 million at quarter-end.
• Medicare coverage expanded for NeXT Personal in IO monitoring, neoadjuvant breast cancer; guidance and earnings calls halted following Tempus merger agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-332748), on August 04, 2026, and is solely responsible for the information contained therein.